Meeting
2022 ASCO Annual Meeting
FGFR2 fusion detection in plasma: A new era in the clinical monitoring of iCCA.
Authors
Alberto Gonzalez-Medina
Cancer Genomics Group, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
Alberto Gonzalez-Medina , Helena Verdaguer , Maria Vila-Casadesús , Alexandre Sierra , Gloria Castillo , Carles Fabregat-Franco , Marina Gómez-Rey , Josep Maria Miquel Aymar , Teresa Macarulla , Ana Vivancos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4085)
DOI
10.1200/JCO.2022.40.16_suppl.4085
Abstract #
4085
Poster Bd #
72
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Emerging treatments for advanced cholangiocarcinoma: Addressing the knowledge gap.
First Author: Elizabeth J Heller
Poster
2020 ASCO Virtual Scientific Program
Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape.
First Author: Melanie A. Krook
Poster
2024 ASCO Annual Meeting
Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.
First Author: Samantha Gage
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.
First Author: Milind M. Javle